A drug for a rare condition which affects 88 people in England has been approved for use, it was announced last night.
The drug for Morquio A syndrome is priced at £400,000 a year – although NHS officials said they had negotiated a “substantial discount” for it.
The drug Elosulfase alfa replaces an enzyme N-acetylgalactosamine-6-sulfatase lacking in patients with the disease, also known as mucopolysaccharidosis type IVa.
The National Institute for Health and Care Excellence said it had found the treatment improved health significantly for some patients.
Under the arrangements, there will be a five year, fixed-fee arrangement known as a “managed access scheme,” aimed at assessing the long-term benefits of the drug.
Dame Barbara Hakin, from NHS England, said: “This agreement will enable us to start treating people with this debilitating condition, assess whether this treatment provides real benefits in the long term and, assuming it does, then continue to provide it in a sustainable way.
“This drug is not a cure but it can have benefits for patients, though long-term outcomes remain uncertain.
“NICE was right to highlight the very high list price, which would have a disproportionate impact on the availability of other treatments. It is good news for all our patients that we have been able to come to a more reasonable arrangement that works for the NHS more broadly.”
Professor Chris Hendriksz, of Salford Royal NHS Foundation Trust, said: “This is fantastic news for all affected patients.
“Many of the patients who participated in the largest ever clinical trial for ultra rare enzyme replacement therapies are from England, and today’s announcement means they and all diagnosed patients in the country will now have a greater opportunity to access treatment.
“Previously, we have only been able to help manage symptoms, but this new treatment is now able to target the underlying cause of this devastating disorder.”

Leave a Reply